Lupin has informed that it enclosed a Press Release regarding completion of an inspection by U.S. FDA of the Company’s Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations.
The above information is a part of company’s filings submitted to BSE.